StreetInsider.com News Articles

Propanc Biopharma launches $5M share repurchase program

Thu, 02 Jul 2026 08:30:35 -0400

Propanc Biopharma, Inc. (NASDAQ: PPCB) announced a share repurchase program authorizing the buyback of up to $5.0 million of its common stock, with an initial tranche of up to $500,000 to be executed over the next 30 days, according to a press release issued July 2, 2026.

Under the program, the company may repurchase shares through open market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, or purchases through 10b5-1 trading plans, subject to market conditions and applicable securities laws.

The program operates pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934. The company stated that the repurchase

Propanc Biopharma Initiates $5.0 Million Share Repurchase Program

Thu, 02 Jul 2026 08:30:00 -0400

The Company to Purchase First Tranche of Up to $500,000 over the next 30-day period

MELBOURNE, Australia, July 02, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced it has initiated a share repurchase program authorizing the Company to repurchase a first tranche of up to $500,000 over the next 30-day period.

“We are pleased to commence this share repurchase program with this initial commitment, as we strongly believe the Company is entering a transformative stage

Propanc Biopharma Initiates $5.0 Million Share Repurchase Program

Thu, 02 Jul 2026 08:30:00 -0400

The Company to Purchase First Tranche of Up to $500,000 over the next 30-day period

“We are pleased to commence this share repurchase program with this initial commitment, as we strongly believe the Company is entering a transformative stage

Propanc Biopharma Initiates $5.0 Million Share Repurchase Program

Thu, 02 Jul 2026 08:30:00 -0400

The Company to Purchase First Tranche of Up to $500,000 over the next 30-day period

“We are pleased to commence this share repurchase program with this initial commitment, as we strongly believe the Company is entering a transformative stage

Propanc Biopharma Initiates $5.0 Million Share Repurchase Program

Thu, 02 Jul 2026 08:30:00 -0400

The Company to Purchase First Tranche of Up to $500,000 over the next 30-day period

“We are pleased to commence this share repurchase program with this initial commitment, as we strongly believe the Company is entering a transformative stage

PROPANC Biopharma CEO visits European CDMO for PRP drug production

Tue, 16 Jun 2026 08:45:22 -0400

Propanc Biopharma, Inc. (NASDAQ: PPCB) announced that its Chief Executive Officer, James Nathanielsz, toured a European contract development and manufacturing organization's GMP facility in preparation for production of the company's lead drug candidate, PRP, according to a press release.

PRP is described as a fixed combination of two proenzymes, trypsinogen and chymotrypsinogen, administered by intravenous injection once weekly. The drug is intended for use in a Phase 1b, first-in-human clinical study enrolling 30 to 40 patients with advanced solid tumor cancers.

During the visit, Propanc's research and development team and personnel from the CDMO discussed proposed project timelines, which include the following

PROPANC Biopharma CEO visits European CDMO for PRP drug production

Tue, 16 Jun 2026 08:45:22 -0400

During the visit, Propanc's research and development team and personnel from the CDMO discussed proposed project timelines, which include the following

PROPANC Biopharma CEO visits European CDMO for PRP drug production

Tue, 16 Jun 2026 08:45:22 -0400

During the visit, Propanc's research and development team and personnel from the CDMO discussed proposed project timelines, which include the following

PROPANC Biopharma CEO visits European CDMO for PRP drug production

Tue, 16 Jun 2026 08:45:22 -0400

During the visit, Propanc's research and development team and personnel from the CDMO discussed proposed project timelines, which include the following

PPCB CEO visits European CDMO ahead of PRP drug manufacturing plan

Tue, 16 Jun 2026 08:45:14 -0400

Propanc Biopharma, Inc. (NASDAQ: PPCB) announced that Chief Executive Officer James Nathanielsz toured a European contract development and manufacturing organization's facility in preparation for the production of the company's lead drug candidate, PRP, ahead of a planned Phase 1b, First-In-Human clinical study.

According to a press release, the visit included discussions between Propanc's research and development team and CDMO personnel on project timelines. The company outlined the following target dates for production milestones: preproduction in August 2026, an engineering run in October 2026, and GMP manufacture commencing in December 2026.

PRP is described as a fixed combination of two proenzymes, trypsinogen and

Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study